Extended-Spectrum β-Lactamase and Multidrug Resistance in Urinary Sepsis Patients Admitted to the Intensive Care Unit
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The role of extended-spectrum β-lactamase (ESBL)-producing or multidrug-resistant (MDR) organisms in patients with sepsis secondary to urinary traction infection (UTI) has not been investigated extensively in the intensive care unit (ICU) setting. Methods: Patients with UTI sepsis admitted to the ICU were retrospectively enrolled in this study (January 2009-December 2012). We investigated the impact of ESBL-producing and ESBL-negative MDR organisms on hospital outcome. Results: In total, 94 patients were enrolled (median age, 73.0 years; female, 81.9%), and ESBL-producing and ESBL-negative MDR organisms accounted for 20.2% (n = 19) and 30.9% (n = 29), respectively. Both patients with ESBL-producing and ESBL-negative MDR organisms were more likely to experience a delay in adequate antibiotic therapy than those with non-ESBL/non-MDR organisms (p < 0.001 and p = 0.032, respectively). However, only patients with ESBL-producing organisms showed a higher mortality rate (ESBL vs. ESBL-negative MDR vs. non-ESBL/non-MDR, 31.6% vs. 10.3%.vs. 10.9%, respectively). In multivariate analyses, ESBL production was significantly associated with hospital mortality (odds ratio, 11.547; 95% confidence interval, 1.047-127.373), and prior admission was a significant predictor of ESBL production. Conclusions: Although both ESBL-producing and ESBL-negative MDR organisms are associated with delayed administration of appropriate antibiotics, only ESBL production is a significant predictor of hospital mortality among patients with UTI sepsis in the ICU setting.
Abstract
Background: The role of extended-spectrum β-lactamase (ESBL)-producing or multidrug-resistant (MDR) organisms in patients with sepsis secondary to urinary traction infection (UTI) has not been investigated extensively in the intensive care unit (ICU) setting. Methods: Patients with UTI sepsis admitted to the ICU were retrospectively enrolled in this study (January 2009-December 2012). We investigated the impact of ESBL-producing and ESBL-negative MDR organisms on hospital outcome. Results: In total, 94 patients were enrolled (median age, 73.0 years; female, 81.9%), and ESBL-producing and ESBL-negative MDR organisms accounted for 20.2% (n = 19) and 30.9% (n = 29), respectively. Both patients with ESBL-producing and ESBL-negative MDR organisms were more likely to experience a delay in adequate antibiotic therapy than those with non-ESBL/non-MDR organisms (p < 0.001 and p = 0.032, respectively). However, only patients with ESBL-producing organisms showed a higher mortality rate (ESBL vs. ESBL-negative MDR vs. non-ESBL/non-MDR, 31.6% vs. 10.3%.vs. 10.9%, respectively). In multivariate analyses, ESBL production was significantly associated with hospital mortality (odds ratio, 11.547; 95% confidence interval, 1.047-127.373), and prior admission was a significant predictor of ESBL production. Conclusions: Although both ESBL-producing and ESBL-negative MDR organisms are associated with delayed administration of appropriate antibiotics, only ESBL production is a significant predictor of hospital mortality among patients with UTI sepsis in the ICU setting.
참고문헌 (37)
- Martin GS, "The epidemiology of sepsis in the United States from 1979 through 2000", N Engl J Med, 348, pp.1546~1554 (2003)
- Brun-Buisson C, "EPISEPSIS Study Group: EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units", Intensive Care Med, 30, pp.580~588 (2004)
- Rosser CJ, "Urinary tract infections in the critically ill patient with a urinary catheter", Am J Surg, 177, pp.287~290 (1999)
- Lu PL, "Epidemiology and antimicrobial susceptibility profiles of gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the study for monitoring antimicrobial resistance trends (SMART)", Int J Antimicrob Agents, 40, pp.S37~S43 (2012)
- Hawser SP, "Emergence of high levels of extended-spectrumbeta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the study for monitoring antimicrobial resistance trends (SMART) program, 2007", Antimicrob Agents Chemother, 53, pp.3280~3284 (2009)
- Frakking FN, "Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria", Antimicrob Agents Chemother, 57, pp.3092~3099 (2013)
- Lin HC, "Risk factors for acquiring extended-spectrum β-lactamase-producing Enterobacteriaceae in geriatric patients with multiple comorbidities in respiratory care wards", Geriatr Gerontol Int, 13, pp.663~671 (2013)
- Park SH, "Emergence of extended-spectrum β-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes", Microb Drug Resist, 17, pp.537~544 (2011)
- Rodríguez-Baño J, "Community-onset bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis", Clin Infect Dis, 50, pp.40~48 (2010)
- Ku NS, "Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia", Arch Gerontol Geriatr, 58, pp.105~109 (2014)
- Nicolle LE, "Urinary tract infection", Crit Care Clin, 29, pp.699~715 (2013)
- Hayakawa K, "Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. medical center", Antimicrob Agents Chemother, 57, pp.4010~4018 (2013)
- Linhares I, "Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009)", BMC Infect Dis, 13, pp.19~ (2013)
- Calandra T, "International Sepsis Forum Definition of Infection in the ICU Consensus Conference: The international sepsis forum consensus conference on definitions of infection in the intensive care unit", Crit Care Med, 33, pp.1538~1548 (2005)
- Dellinger RP, "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012", Intensive Care Med, 39, pp.165~228 (2013)
- Friedman ND, "Healthcare--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections", Ann Intern Med, 137, pp.791~797 (2002)
- Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement M100-S17", CLSI, ~ (2007)
- 대한감염학회, "요로 감염 임상진료지침 권고안: 무증상 세균뇨, 단순 요로감염, 복잡성 요로감염, 세균성 전립선염", Infection and Chemotherapy, 43(1), pp.1~25 (2011), 대한감염학회
- Briongos-Figuero LS, "Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria", Int J Clin Pract, 66, pp.891~896 (2012)
- Sader HS, "Frequency of occurrence and antimicrobial susceptibility of gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009-2011)", J Chemother, 26, pp.133~138 (2014)
- Zilberberg MD, "Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009", Infect Control Hosp Epidemiol, 34, pp.940~946 (2013)
- Lin JN, "Clinical characteristics and outcomes of patients with extended-spectrum β-lactamase-producing bacteremias in the emergency department", Intern Emerg Med, 6, pp.547~555 (2011)
- Lye DC, "The impact of multidrug resistance in healthcare-associated and nosocomial gram-negative bacteraemia on mortality and length of stay: cohort study", Clin Microbiol Infect, 18, pp.502~508 (2012)
- Hoban DJ, "Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the study for monitoring antimicrobial resistance trends (SMART) program:2009-2010", Diagn Microbiol Infect Dis, 70, pp.507~511 (2011)
- Jean SS, "Nationwide surveillance of antimicrobial resistance among Enterobacteriaceae in intensive care units in Taiwan", Eur J Clin Microbiol Infect Dis, 28, pp.215~220 (2009)
- Azap OK, "Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections", Clin Microbiol Infect, 16, pp.147~151 (2010)
- 이동섭, "Prevalence and Risk Factors for Extended Spectrum Beta-Lactamase-Producing Uropathogens in Patients with Urinary Tract Infection", Investigative and Clinical Urology, 51(7), pp.492~497 (2010), 대한비뇨기과학회
- Rottier WC, "Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis", J Antimicrob Chemother, 67, pp.1311~1320 (2012)
- Rodríguez-Baño J, "Clinical significance of extended-spectrum beta-lactamases", Expert Rev Anti Infect Ther, 6, pp.671~683 (2008)
- Kang CI, "Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy", Antimicrob Agents Chemother, 48, pp.4574~4581 (2004)
- 강철인, "광범위 베타 락탑계 항생제 분해효소를 생성하는 폐렴간균에 의한 균혈증이 발생한 환자에서 감염의 위험 인자 및 치료 결과", Infection and Chemotherapy, 35(2), pp.61~70 (2003), 대한감염학회
- Park SH, "The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli", J Antimicrob Chemother, 69, pp.2848~2856 (2014)
- Chang R, "Epidemiology of hospital-acquired urinary tract-related bloodstream infection at a university hospital", Infect Control Hosp Epidemiol, 32, pp.1127~1129 (2011)
- Menashe G, "Clinical significance and impact on mortality of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia", Scand J Infect Dis, 33, pp.188~193 (2001)
- Kim BN, "Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia", J Hosp Infect, 52, pp.99~106 (2002)
- Wang F, "Brain natriuretic peptide for prediction of mortality in patients with sepsis: a systematic review and meta-analysis", Crit Care, 16, pp.R74~ (2012)
- Hur M, "Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis", BMC Infect Dis, 14, pp.224~ (2014)